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ABSTRACT 
Hepatitis C is a major global health burden and Egypt has the highest prevalence of hepatitis 
C virus (HCV) worldwide. The current study was designed to evaluate the beneficial thera-
peutic effects of ethanolic extracts of Nigella sativa, Zingiber officinale and their mixture in 
Egyptian HCV patients. Sixty volunteer patients with proven HCV and fifteen age matched 
healthy subjects were included in this study. Exclusion criteria included patients on interferon 
alpha (IFN-α) therapy, infection with hepatitis B virus, drug-induced liver diseases, advanced 
cirrhosis, hepatocellular carcinoma (HCC) or other malignancies, blood picture abnormalities 
and major severe illness. Liver function enzymes, albumin, total bilirubin, prothrombin time 
and concentration, international normalized ratio, alpha fetoprotein and viral load were all as-
sessed at baseline and at the end of the study. Ethanolic extracts of Nigella sativa and Zingi-
ber officinale were prepared and formulated into gelatinous capsules, each containing 500 mg 
of Nigella sativa and/or Zingiber officinale. Clinical response and incidence of adverse drug 
reactions were assessed initially, periodically, and at the end of the study. Both extracts as 
well as their mixture significantly ameliorated the altered viral load, alpha fetoprotein, liver 
function parameters; with more potent effect for the combined therapy. In conclusion, admin-
istration of Nigella sativa and/or Zingiber officinale ethanolic extracts to HCV patients exhib-
ited potential therapeutic benefits via decreasing viral load and alleviating the altered liver 
function, with more potent effect offered by the mixture. 
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INTRODUCTION 
Hepatitis C virus (HCV) infection often 
is conducive to chronic hepatitis due to the 
low viral clearance rate, leading to liver cir-
rhosis (LC) and subsequent progression to 
hepatocellular carcinoma (HCC) (Alter, 
2007; Lavanchy, 2011). It has been shown 
that there is an alarming increase in the in-
cidence of HCC in HCV patients in Egypt 
(Anwar et al., 2008). According to the 
EXCLI Journal 2013;12:943-955 – ISSN 1611-2156 
Received: July 31, 2013, accepted: October 28, 2013, published: November 11, 2013 
 
 
944 
World Health Organization (WHO) there 
are 130-170 million people infected with 
the hepatitis C virus, corresponding to 2-
2.5 % of the world’s total population 
(WHO, 2013). Egypt has the highest preva-
lence of HCV worldwide (15 %) and the 
highest prevalence of HCV-4 (67 %) with a 
predominance of subtype 4a (55 %) (Ngu-
yen and Keeffe, 2005; Elkady et al., 2009; 
Khattab et al., 2011, WHO, 2013). 
The standard therapy, which is based on 
a combination of pegylated interferon alpha 
(IFN-α) and ribavirin (McHutchison et al., 
1998), results in highly variable outcomes, 
is very expensive and has severe side ef-
fects that are difficult to endure for the pa-
tients (Di Bisceglie and Hoofnagle, 2002; 
Calland et al., 2012). Therefore, the estab-
lishment of a new treatment modality with-
out serious adverse effects is desirable 
(Vermehren and Sarrazin, 2011). 
Medicinal plants have been found to 
play a major role in managing human dis-
eases. Historically, numerous important 
modern drugs have been developed from 
molecules originally isolated from natural 
sources (Lee, 2000; Balunas and Kinghorn, 
2005). The search for new bioactive mole-
cules in plants in key therapeutic areas such 
as immunosuppression, infectious diseases, 
cancer and metabolic disorders is still an 
active part of pharmaceutical research 
(Newman and Cragg, 2012). About 40 new 
drugs launched on the market between 2000 
and 2010, originate from terrestrial plants, 
terrestrial microorganisms, marine organ-
isms, and terrestrial vertebrates and inver-
tebrates (Brahmachari, 2011). 
Ginger (Zingiber officinale) is a well-
known and widely used herb, which con-
tains several interesting bioactive constitu-
ents and possesses health-promoting prop-
erties (Ajayi et al., 2013). From its origin in 
Southeast Asia and its spread to Europe, it 
has a long history of use as herbal medicine 
to treat a variety of ailments including vom-
iting, pain, indigestion, and cold induced 
syndromes (White, 2007). More recently, it 
was reported that ginger also possessed an-
ti-cancer, anticlotting, anti-inflammatory, 
and analgesic activities (Chrubasik et al., 
2005; Ali et al., 2008). 
Nigella sativa (N. sativa) is used as a 
food condiment in the Middle East, and its 
seeds/oil have been shown to possess anti-
inflammatory, antiviral and antineoplastic 
activity in various in vitro and in vivo stud-
ies (Zaher et al., 2008). There are many re-
ports of its biological activities including: 
immunopotentiation, antitumor, anti-
inflammatory, analgesic, antihypertensive, 
antidiabetic, respiratory stimulation, anti-
bacterial, antifungal, anticestode and 
antinematode effects (Ali and Blunden, 
2003; Al-Naggar et al., 2003). 
To date, studies addressed the use of 
ethanolic extracts of Z. officinale, N. sativa 
and their mixture in HCV patients are 
scanty. Hence, we sought to evaluate the 
efficacy, safety, and tolerability of Z. offici-
nale and N. sativa extracts, individually and 
in combination, as an alternative therapy in 
the management of HCV patients. 
 
MATERIALS AND METHODS 
This was a prospective, single-armed, 
self-controlled pilot study, conducted at the 
Hepatology Unit, Gastroentrology Depart-
ment, Beni-Suef University Hospital, Beni-
Suef University, Egypt. 
 
Patients 
Sixty volunteer patients with proven 
chronic HCV who were selected from ad-
mitted patients at the Hepatology Unit, Be-
ni-Suef University Hospital, with fifteen 
age-matched healthy controls were included 
in this study. 
Inclusion criteria included all patients 
diagnosed with HCV and negative for 
HBV. Exclusion criteria included patients 
on IFN-α therapy; infection with HBV or 
hepatitis immunodeficiency virus; drug-
induced liver diseases; advanced cirrhosis; 
HCC or other malignancies; blood picture 
abnormalities such as anemia (hemoglobin 
concentration of 10 g/dl or less), leucopenia 
(white blood cells 1.500/µl or less) and 
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thrombocytopenia (platelets count 80.000/µl 
or less); major severe illness such as renal 
failure, congestive heart failure, respiratory 
failure or autoimmune disease; or non-
compliance to treatment. Informed consent 
was obtained from all patients, and the in-
stitutional ethical committee approved the 
study protocol, which conformed with the 
ethical guidelines of the 1975 Declaration 
of Helsinki. 
 
Extract preparation 
N. sativa seeds and Z. officinale rhi-
zomes were purchased from the local herb-
alist in Egypt. The seeds and rhizomes were 
authenticated by a specialist of Plant Tax-
onomy in Botany Department, Faculty of 
Science, Beni-Suef University, Egypt. Both 
were cleaned, dried, mechanically pow-
dered, extracted with 96 % ethanol and 
evaporated with rotary evaporator to render 
the extract alcohol free. The extracts were 
made into soft gelatin capsules, each con-
taining 500 mg of N. sativa and/or Z. offici-
nale extracts. The above procedures were 
undertaken in the Arab Company for Phar-
maceuticals & Medicinal Plants (Mepaco-
Medifood), Enshas EL Raml, Sharkeiya 
Factory, Sharkeiya, Egypt. 
 
Treatment protocol 
Included patients and controls were 
classified into five groups each comprising 
fifteen patients as follows; Group 1 served 
as healthy subjects; Group 2 (HCV) served 
as HCV control; Group 3 (HCV+N) re-
ceived a capsule containing 500 mg N. sati-
va extract twice daily; Group 4 (HCV+G) 
received a capsule containing 500 mg Z. 
officinale extract twice daily and Group 5 
(HCV+NG) received a capsule containing 
500 mg of each extract twice daily. Patients 
were followed up weekly throughout the 
study period for assessing treatment adher-
ence, tolerability and incidence of adverse 
reactions. 
 
Clinical and laboratory assessment 
All eligible patients and controls were 
subjected to the following at enrollment and 
after 1 month therapy: (1) Full clinical as-
sessment with an emphasis on hepato- 
and/or splenomegaly, jaundice, palmar ery-
thema, flapping tremors, spider naevi, low-
er-limb edema, and ascites; (2) Laboratory 
investigation of liver functions including 
aspartate aminotransferase (AST) and ala-
nine aminotransferase (ALT) were assayed 
according to the method of Schumann and 
Klauke (2003) using reagent kit purchased 
from Noble Diagnostic (Egypt); lactate de-
hydrogenase (LDH) was determined ac-
cording to the method of Teitz (1986) using 
reagent kit purchased from Human (Ger-
many); alkaline phosphatase (ALP) was 
assayed according to the International Fed-
eration of Clinical Chemistry (IFCC, 1980) 
using BioSystem (Spain) commercial kit, 
gamma glutamyl transferase (γGT) assay 
was performed according to Persijn and van 
der Slik (1976) using kits from Reactivos 
GPL (Spain); albumin was assayed accord-
ing to the method of Webster (1974) using 
kits of Diamond Diagnostic (Egypt); total 
bilirubin, was determined using reagent kit 
purchased from Diamond Diagnostic 
(Egypt), according to the method of Kaplan 
(1984) and prothrombin time (PT), pro-
thrombin concentration (PC) and interna-
tional normalized ratio (INR) were deter-
mined according to the method of Wanger 
and Dati (1998) using kits supplied by Sie-
mens Healthcare Diagnostic (USA) and (3) 
Serum α-fetoprotein (AFP) was assayed 
according to Forest and Pugeat (1987) us-
ing kits purchased from VIDAS bio 
Merieux (France) and quantitative real time 
polymerase chain reaction (qRT-PCR) for 
HCV using Roche Amplicor HCV monitor 
version 2.0 (Roche Diagnostics, Branch-
burg, NJ), with lower detection limit < 50 
IU/ml. 
 
Statistical analysis 
The data were statistically analyzed us-
ing SPSS v.16. Results were expressed as 
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Mean ± Standard error (SE) and all statisti-
cal comparisons were made by means of 
one-way ANOVA test followed by Dun-
can’s multiple range test post hoc analysis. 
A P value less than 0.05 was considered 
significant. 
 
RESULTS 
The effects of N. sativa, Z. officinale 
and their mixture on viral load of control 
and treated patients were depicted in Figure 
1. After one month treatment with N. sativa 
and/or Z. officinale ethanolic extracts, pa-
tients exhibited a significant (P<0.001) de-
crease in viral load as compared to HCV 
control group. The recorded data were 
145.13 ± 26.93, 152.13 ± 29.73 and 102.93 
± 12.89 for HCV+N, HCV+G and 
HCV+NG groups, respectively. Treatment 
with the mixture of both extracts seemed to 
be the most effective in reducing viral load 
and there were five cases who showed a 
non-detectable viremia. 
 
 
Figure 1: Viral load in control and treated pa-
tients. Data are expressed as mean ± SE, 
means which share the same superscript sym-
bol(s) are not significantly different, P<0.001. 
 
 
The serum concentrations of AFP were 
significantly (P<0.001) elevated in HCV 
control patients as compared to the corre-
sponding healthy subjects (Figure 2). On 
the other hand, all treatments were very ef-
fective in alleviating the elevated AFP lev-
els. However, while all used treatments 
have more or less similar effects, the used 
mixture seemed to be more effective in re-
ducing serum AFP levels. 
 
 
Figure 2: Serum AFP in healthy, HCV control 
and treated patients. Data are expressed as 
mean ± SE, means which share the same su-
perscript symbol(s) are not significantly differ-
ent, P<0.001. 
 
The activities of serum liver marker en-
zymes, AST, ALT, γGT, LDH and ALP, 
were represented in Figure 3a-e. The HCV 
control group exhibited significantly 
(P<0.001) elevated serum activities of all 
assayed enzymes when compared to the 
corresponding healthy subjects. Admin-
istration of N. sativa, Z. officinale and their 
mixture significantly (P<0.001) ameliorated 
the elevated liver marker enzymes. Al-
though there were non-significant differ-
ences between the administered treatments 
on liver marker enzymes, mixture of both 
extracts offered more potent effect on de-
clining the elevated enzyme activities. 
Serum albumin of the HCV control 
group exhibited a significant (P<0.001) de-
crease in comparison to healthy control 
group. On the other hand, serum total bili-
rubin showed an opposite pattern, where it 
was significantly (P<0.001) elevated in 
HCV control patients as compared to their 
corresponding healthy subjects (Table 1). 
Similarly, PT and INR were significantly 
(P<0.01) elevated in HCV control group, 
while PC was significantly (P<0.05) de-
clined. All previously mentioned parame-
ters were potentially improved following 
treatment with N. sativa and/or Z. offici-
nale.
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Figure 3: Serum liver enzymes of healthy, HCV control and HCV treated patients; (a) ALT, (b) AST, 
(c) γGT, (d) LDH and (e) ALP. Data are expressed as mean ± SE, means which share the same su-
perscript symbol(s) are not significantly different, P<0.001. 
 
 
DISCUSSION 
Chronic hepatitis C is a major global 
health burden with an estimated 160 million 
infected individuals worldwide. This long-
term disease evolves slowly, often leading 
to chronicity and potentially to liver failure 
(Calland et al., 2012). The lack of vaccine 
for HCV infections, the high cost of the 
drugs specially in low-income countries 
with a high prevalence of HCV, ineffective 
therapy and the rapid emergence of new 
drug-resistant viruses have urged a growing 
need for developing new, more effective 
chemotherapeutic agents with less side ef-
fects for successful HCV treatment (Sheir 
et al., 2013). In the current study, admin-
istration of N. sativa, Z. officinale and their 
mixture resulted in a significant decrease in 
viral load and AFP, with a more potent ef-
fect offered by the mixture. We hypothe-
sized that efficacy of the mixture might be 
attributed to the synergistic effect of the 
included active compounds. 
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Table 1: Albumin, total bilirubin, PT, PC and INR in healthy, HCV and HCV treated patients 
 Albumin 
(g/dl) 
Total Bilirubin 
(mg/dl) 
PT 
(Sec) 
PC 
( %) 
INR 
Healthy 4.57 ± 0.09a 0.21 ± 0.03c 12.86 ± 0.06b 95.68 ± 0.65c 1.05 ± 0.01b 
HCV Control 3.69 ± 0.09b 0.83 ± 0.08a 13.69 ± 0.19a 88.61 ± 1.47d 1.13 ± 0.02a 
HCV + N 4.32 ± 0.11a 0.37 ± 0.07bc 11.93 ± 0.24d 105.94 ± 2.89a 0.95 ± 0.02d 
HCV + G 4.29 ± 0.11a 0.46 ± 0.05b 12.49 ± 0.24cb 99.75 ± 2.35cb 1.01 ± 0.03bc 
HCV + NG 4.47 ± 0.08a 0.42 ± 0.06b 12.17 ± 0.14cd 102.68 ± 1.55ab 0.98 ± 0.02cd 
F-Prob. P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 
Data are expressed as mean ± SE, means which share the same superscript symbol(s) are not signifi-
cantly different. 
 
Barakat et al. (2013) revealed that N. 
sativa administration resulted in a signifi-
cant decrease in viral load, with 16.67 % of 
patients becoming seronegative, and 50 % 
showing a significant decrease in the quan-
titative viral count. Among these, 66.7 % 
had cirrhosis and 33.3 % had chronic liver 
disease, implying antiviral activity. Also, 
the anti-inflammatory, antiviral and 
antineoplastic activities of N. sativa have 
been previously documented in various in 
vitro and in vivo studies (Zaher et al., 
2008). To our best knowledge no studies 
have explored the therapeutic effects of Z. 
officinale extract in HCV patients. Hence, 
we assumed that the observed beneficial 
therapeutic effects of the used extract might 
be attributed to its rich content of the anti-
oxidant and anti-inflammatory compounds. 
It is relevant here to mention the in-
volvement of oxidative stress in the patho-
genesis of hepatic dysfunction in human 
which has been investigated for many years 
(Spirli et al., 2001; Alpini et al., 2002; Ce-
saratto et al., 2004; Jabłonowska et al., 
2005). HCV infection often leads to liver 
fibrosis and cirrhosis, various metabolic 
alterations including steatosis, insulin and 
interferon resistance, and development of 
hepatocellular carcinoma or non-Hodgkin 
lymphoma. Multiple molecular mechanisms 
that trigger the emergence and development 
of each of these pathogenic processes have 
been identified so far. One of these involves 
marked induction of reactive oxygen spe-
cies (ROS) in infected cells leading to oxi-
dative stress (Ivanov et al., 2013). In addi-
tion, HCV-related fibrosis, cirrhosis and 
liver failure have been found to be the re-
sult of an adaptive immune response to 
HCV-infected cells (Nelson, 2001), which 
is mediated by induction of endoplasmic 
reticulum and oxidative stress, and down-
regulation of the antiapoptotic proteins, nu-
clear factor-κB and Bcl-xl, in infected 
hepatocytes (Joyce and Tyrrell, 2010). 
Thymoquinone, the main constituent of 
N. sativa seeds, protects organs against oxi-
dative damage induced by a variety of free 
radical generating pathologies (Tekeoglu et 
al., 2007; Kanter, 2008; Radad et al., 2009). 
In addition, many studies have addressed 
the hepatoprotective effects of thymoqui-
none (Nagi and Mansour, 2000; Meral et 
al., 2001; El-Dakhakhny et al., 2002; 
Mahmoud et al., 2002). Furthermore, a 
study by Salem and Hossain (2000) record-
ed a striking reduction of murine cytomeg-
alovirus titer in both spleen and liver of 
mice treated with N. sativa compared with 
control mice. 
Regarding antioxidant content, Z. offici-
nale is the third amongst 1000 food items 
analysed by Halvorsen et al. (2006). [6]-
Dehydroshogaol, [6]-shogaol and 1-
dehydro-[6]-gingerdione were shown to be 
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potent inhibitors of nitric oxide (NO) syn-
thesis in activated macrophages as reported 
by Li et al. (2011). The antioxidant activity 
of [6]-gingerol against linoleic acid autoxi-
dation and phospholipids peroxidation has 
been demonstrated earlier (Ippoushi et al., 
2003). In addition, it has been found to pro-
tect against cellular damages induced by 
peroxynitrite (Ippoushi et al., 2003). It pro-
tected DNA from lipopolysaccharide-
induced oxidation damage in rats (Ippoushi 
et al., 2007). In the study conducted by Du-
gasani et al. (2010), [6]-shogaol has exhib-
ited the most potent antioxidant properties, 
compared to [6]-gingerol, [8]-gingerol and 
[10]-gingerol. The recorded antioxidant ef-
ficacy of [6]-shogaol can be attributed to 
the presence of α,β-unsaturated ketone moi-
ety (Dugasani et al., 2010). Moreover, the 
contained phenolic compounds of ginger, 
such as gingerol and shogoal, possess anti-
oxidant (Jeyakumar et al., 1999), anti-
cancer (Shukla and Singh, 2007), anti-
inflammatory (Hudson et al., 2006; Habib 
et al., 2008), anti-angiogenesis (Huang et 
al., 2000) and anti-artherosclerotic proper-
ties (Coppola and Novo, 2007). Further-
more, the phagocytic activity of blood leu-
kocytes was increased in rainbow trout fed 
with plant extracts containing food, espe-
cially 1 % ginger (Dügenci et al., 2003). 
Zhou et al. (2006) demonstrated that the 
volatile oil of ginger influences both cell-
mediated immune response and non-
specific proliferation of T lymphocyte, and 
may exert beneficial effects in a number of 
clinical conditions, such as chronic inflam-
mation and autoimmune diseases. Hence, 
the observed antiviral potential of N. sativa 
and/or Z. officinale was mediated through 
their antioxidant, immunomodulatory and 
anti-inflammatory efficacies. 
The role of liver enzymes in the as-
sessment of chronic hepatitis C remains 
important due to the fact that the majority 
of clinical indexes estimating the degree of 
liver fibrosis are based on liver transami-
nases (Giannini and Testa, 2003; Forns et 
al., 2004; Lackner et al., 2005). These en-
zymes are considered the most sensitive 
markers of liver injury as they are found in 
the cytoplasm of liver cells, thus damage of 
these cells lead to their rapid leakage into 
the blood circulation (Ramaiah, 2007). The 
present investigation showed a significant 
increase in serum ALT, AST, LDH, γGT 
and ALP activities and total bilirubin levels 
of untreated HCV patient as compared to 
healthy subjects. The significantly elevated 
liver enzymes could be attributed to viral-
induced hepatocellular damage. On the oth-
er hand, administration of N. sativa, Z. of-
ficinale and their mixture greatly improved 
the altered serum liver enzymes and this 
may be mediated through their hepatopro-
tective effects. 
In consistent with our results, a recent 
study by Barakat et al. (2013) showed that 
N. sativa seed oil potentially alleviated se-
rum liver marker enzymes in Egyptian 
HCV patients. They also revealed that N. 
sativa oil administration was tolerable, safe, 
decreased viral load, and improved oxida-
tive stress and clinical condition. Mallikar-
juna et al. (2008) demonstrated that oral 
administration of 200 mg/kg ginger etha-
nolic extract along with country-made liq-
uor significantly alleviated the elevated se-
rum AST, ALT and ALP activities as well 
as tissue lipid peroxide levels in experi-
mental animals. Moreover, Lebda et al. 
(2012) reported that rabbits fed with basal 
diet supplemented with 2 % ginger powder 
and ginger extract; hot and cold for 30 days 
showed significant decrease of serum AST, 
ALT, ALP and γGT activities as compared 
with control group. Furthermore, many 
studies had addressed the potent hepatopro-
tective effect of ginger extract in induced 
hepatotoxicity (Mallikarjuna et al., 2008; 
El-Sharaky et al., 2009; Motawi et al., 
2011). 
Serum albumin is the most abundant 
plasma protein (Don and Kaysen, 2004) and 
is essential for maintaining oncotic pressure 
of the vascular system (Quinlan et al., 
2005). Serum albumin and prothrombin 
time can be considered useful tools, alone 
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or combined in clinical scores, for evaluat-
ing liver function (Botta et al., 2003). 
Chronic HCV patients may suffer a de-
crease in serum albumin level (Mason et al., 
1999), and improvement in hypoalbu-
minemia has been shown to improve prog-
nosis (Nagao and Sata, 2010) and quality of 
life (Kotoh et al., 2005). In addition, a re-
cent study by Shin and Moon (2010) re-
ported that in chronic liver diseases, the se-
rum albumin level is reduced due to protein 
synthesis disruption in the liver. In the cur-
rent study, administration of ginger and N. 
sativa as well as their mixture significantly 
increased serum albumin levels, indicating 
an improvement in clinical condition. Prior 
studies have shown similar effects of N. sa-
tiva administration to animals (Al-Gaby, 
1998; Tollba and Hassan, 2003; Shewita 
and Taha, 2011) and to HCV patients 
(Barakat et al., 2013). Similarly, Motawi et 
al. (2011) revealed the potency of Z. offici-
nale in alleviating serum total protein and 
bilirubin levels in carbon tetrachloride-
induced liver fibrosis in rats. 
Therefore, the potent therapeutic effects 
offered by the mixture of N. sativa and Z. 
officinale in this study may be attributed to 
the synergism between their active constit-
uents. Guimarães et al. (2011) reported that 
the most potent antioxidant activity was 
found in combinations of different herbs, 
suggesting synergistic effects. So the syn-
ergistic effect of using mixture of herbs are 
designed to work together to produce a gen-
tle, balanced and greater effect to correct 
underlying imbalances than temporary re-
lief (Liu and Du, 2012; Sarg et al., 2012; 
Rajput and Mandal, 2012). 
In conclusion, our findings suggest that 
administration of both N. sativa and/or Z. 
officinale ethanolic extracts to HCV pa-
tients was safe, tolerable, decreased viral 
load, and improved clinical condition. In 
addition, the current study recommends the 
use of mixtures of herbal therapy to in-
crease their synergetic effects against HCV 
and decrease their side effects. 
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